Observational studyEndocrinology, diabetes & metabolism2022

Clinical outcomes in high-hypoglycaemia-risk patients with type 2 diabetes switching to insulin glargine 300 U/mL versus a first-generation basal insulin analogue in the United States : Results from the DELIVER High Risk real-world study.

Sean D Sullivan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.